Novartis, a global innovative medicines company, has opened a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California, representing a key milestone in the company’s previously announced $23 billion investment in U.S. infrastructure over the next five years. The opening of the Carlsbad manufacturing facility allows Novartis to seamlessly meet future demand for RLT, adding additional capacity and improving the company’s supply chain capabilities. The Carl...